Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
m |
m (→Regimen) |
||
Line 39: | Line 39: | ||
|1992-1998 | |1992-1998 | ||
|style="background-color:#1a9851"|Phase III (C) | |style="background-color:#1a9851"|Phase III (C) | ||
− | |Mifepristone | + | |[[#Mifepristone_99|Mifepristone]] |
| style="background-color:#ffffbf" |Did not meet primary endpoint of FFS | | style="background-color:#ffffbf" |Did not meet primary endpoint of FFS | ||
|- | |- |
Revision as of 02:31, 12 February 2022
Section editor | |
---|---|
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase III (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701